The study by Professor Dr. Stefan Offermanns, Medical Director of the Institute of Pharmacology at Heidelberg University, and his study group in cooperation with colleagues at the German Cancer Research Center in Heidelberg as well as at Frankfurt University and the Max Planck Institute in Bad Nauheim was published online in "The Journal of Experimental Medicine".
Anaphylactic shock is an acute, life-threatening allergic reaction, usually brought on by medication, insect stings, or other allergens, which has become more frequent in recent decades. In sensitised persons, the presence of the allergen leads to the release of various substances (mediators) from immune cells in the blood. These mediators, e.g. histamine or leukotriene, cause an abrupt drop in blood pressure, lowering of body temperature, arrhythmia, respiratory distress, and acute reactions in stomach, bowels and skin. The combination of reactions leads to the life-threatening situation known as anaphylactic shock.
The mediators develop their effect via so-called G protein-coupled receptors that are found on different body cells, among others, in the walls of blood vessels. They trigger signals in the cells that then cause the typical symptoms of an anaphylactic reaction. "In the genetic mouse model, we showed that surprisingly, selective suppression of the genes coding for the G proteins Gq and G11 in vessel walls protected the animals from the most severe anaphylactic reactions", stated Professor Offermanns. Now the road is open for developing and testing substances that could be used directly to inhibit the triggering mechanism.
References:
Anaphylactic shock depends on endothelial Gq/G11. Hanna Korhonen, Beate Fisslthaler, Alexandra Moers, Angela Wirth, Daniel Habermehl, Thomas Wieland, Günther Schütz, Nina Wettschureck, Ingrid Fleming, and Stefan Offermanns; Journal of Experimental Medicine JEM published January 26, 2009










View online magazine